Literature DB >> 11493333

Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma.

H Yamato1, K Ohshima, J Suzumiya, M Kikuchi.   

Abstract

AIMS: Pyothorax-associated lymphoma (PAL) develops in the pleural cavity of patients with a long history of pyothorax. Epstein-Barr virus (EBV) is also involved in PAL, similar to lymphomas in immunodeficient patients. Here we examined T-lymphocyte subsets as well as c-myc and REL gene amplification in PAL tissues. METHODS AND
RESULTS: We determined the number and distribution of CD4+ and CD8+ T-lymphocytes, to evaluate T-cells in the host immune reaction in seven cases of PAL. As controls, we also studied 10 cases of extranodal diffuse large B-cell lymphoma (DLBL) and 10 cases of nodal DLBL. Chromosomal imbalances in PAL were determined by using comparative genomic hybridization (CGH) analysis. The mean numbers of CD4+ and CD8+ and their ratio were significantly lower in PAL than in nodal DLBL. CGH analysis of PAL showed amplification of the 8q24 chromosomal region. In addition, c-myc amplification was found in four cases of PAL by Southern blot analysis.
CONCLUSIONS: Our results suggest that the development of PAL may involve a local immunosuppressive environment and that amplification of c-myc might promote tumour progression, as has been described in the development of Burkitt's lymphoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493333     DOI: 10.1046/j.1365-2559.2001.01197.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Epstein-Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing.

Authors:  Yasuo Sugita; Mizuhiko Terasaki; Daisuke Niino; Koichi Ohshima; Arakawa Fumiko; Minoru Shigemori; Yasuharu Sato; Naoko Asano
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  The c-Rel Transcription Factor in Development and Disease.

Authors:  Thomas D Gilmore; Steve Gerondakis
Journal:  Genes Cancer       Date:  2011-07

3.  EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1.

Authors:  Yasodha Natkunam; John R Goodlad; Amy Chadburn; Daphne de Jong; Dita Gratzinger; John K C Chan; Jonathan Said; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 4.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.

Authors:  Chi Young Ok; Ling Li; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

5.  Primary diffuse large B-cell lymphoma of the chest wall: a case report.

Authors:  Xiaoming Qiu; Yi Liu; Yanjie Qiao; Gang Chen; Tao Shi; Jun Chen; Qinghua Zhou
Journal:  World J Surg Oncol       Date:  2014-04-22       Impact factor: 2.754

Review 6.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

7.  Primary diffuse large B-cell lymphoma as a chest-wall mass: A case report.

Authors:  Qianwen Zhang; Yuanrong Ju; Tao Qu; Tao Wang; Xiaoqin Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 8.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 9.  Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.

Authors:  Carlos A Tirado; Weina Chen; Rolando García; Kelly A Kohlman; Nagesh Rao
Journal:  J Hematol Oncol       Date:  2012-09-11       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.